FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Briviact (brivaracetam) from UCB, authorizing changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy
• Partial-onset Seizures

Drugs mentioned

• Briviact (brivaracetam)

Snippet

SUPPL AP for BRIVIACT (BRIVARACETAM)